Abstract
Background The ZFHX3 gene is highly expressed in the developing brain and plays vital roles in embryonic development, cell proliferation, neuronal differentiation, and neuronal death. The association between the ZFHX3 gene and human disease was not defined.
Methods Whole-exome sequencing was performed in a cohort of 378 patients with partial (focal) epilepsy of childhood. A Drosophila Zfh2 knockdown model was used to validate the association between ZFHX3 and epilepsy. The expression profile of the ZFHX3 ortholog was assessed by RT-qPCR and the data from the Brainspan database.
Results Eight pairs of compound heterozygous variants in ZFHX3 were identified in eight unrelated cases with partial epilepsy. The identified ZFXH3 variants had low or no frequencies in the populations of gnomAD. The ZFHX3 gene presented significantly higher excesses of variants in the case cohort, including a higher excess of biallelic variants than the expected number of East Asian populations, higher aggregated frequencies than that in gnomAD, and a higher frequency of compound heterozygous variants than that in the asymptomatic parent controls. In Zfh2 knockdown flies, the incidence and duration of seizure-like behavior were significantly higher than those of the controls. The Zfh2 knockdown flies exhibited more firing in excitatory neurons than the wild-type line in electrophysiological recordings. All patients with ZFHX3 compound heterozygous variants presented focal seizures and focal discharges on EEGs. One patient experienced frequent nonconvulsive status epilepticus, and two patients evolved from early spasms; the three cases also had neurodevelopmental abnormalities. However, all patients achieved seizure-free. In Drosophila, the expression of Zfh2 is high in larvae and decreased in pupae and early adults. In mice, Zfhx3 is predominantly expressed in fetuses and decreases dramatically after birth. In humans, the data from the Brainspan database showed that ZFHX3 is highly expressed in the embryonic period and decreased after birth.
Conclusion This study suggested that ZFHX3 is potentially a novel causative gene of partial epilepsy of childhood and infantile spasms. The correlation between the outcome and gene expression stage provided insight into the underlying mechanism of the natural course of illness, potentially being helpful in the management of the patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the National Natural Science Foundation of China (Grant Nos. 82271505, 81870903, and 81971216); Science and Technology Project of Guangzhou (Grant No. 202201020106), Multicenter Clinical Research Fund Project of the Second Affiliated Hospital of Guangzhou Medical University (Grant Nos. 010G271099, 2020-LCYJ-DZX-03, and 2021-LCYJ-DZX-02), and Scientific Research Project of Guangzhou Education Bureau (Grant No. 202235395). The funders had no role in the study design, data collection and analysis, and the decision to publish or in manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of The Second Affiliated Hospital of Guangzhou Medical University (2020-h5-49), and written informed consent was obtained from all patients or their parents.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
minor revision in main text and figure
Data Availability
Raw data were generated at Institute of Neuroscience, The Second Affiliated Hospital of Guangzhou Medical University. Derived data supporting the findings of this study are available from the corresponding author on request.